Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

HCW starts MediWound at buy; PT $5.50

H.C. Wainwright initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and price target of $5.50. The stock closed at $2.58 on Aug. 2. MediWound is developing proteolytic enzyme-based eschar debridement...

August 5, 2019

Markets

Piper cuts Intersect ENT to neutral; PT to $17 from $30

Piper Jaffray downgraded Intersect ENT (NASDAQ:XENT) to “neutral” from “overweight” and slashed its price target to $17 from $30 after the company reported second quarter results and lowered its revenue guidance to flat...

August 2, 2019

Markets

AGP cuts T2 Biosystems to neutral; PT 40 cents

Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” with a price target of 40 cents after the company reported second quarter results. The stock closed at 59 cents on Aug. 1. The...

August 2, 2019

Developments

AC Immune initiates Phase 1b/2a trial of Alzheimer’s disease vaccine

AC Immune (NASDAQ:ACIU) initiated a Phase 1b/2a clinical trial to evaluate its anti-phospho-Tau vaccine in patients with early Alzheimer’s disease (AD). Targeting pathological Tau, the vaccine is intended as a disease...

August 1, 2019

Developments

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

The European Commission (EC) granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor orphan drug designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

August 1, 2019

Developments

BTIG cuts Conformis to neutral

BTIG downgraded Conformis (NASDAQ:CFMS) to “neutral” from “buy” following release of the company’s second quarter results. BTIG does not publish price targets on neutral-rated stocks. Conformis, which closed at $2.76 on...

August 1, 2019

Markets

Exicure to uplist to NASDAQ; prices $55-million public offering

Exicure’s (OTCQB:XCUR) common stock will begin trading on the Nasdaq Capital Market under the symbol “XCUR” at the opening of trading on July 31, 2019. Exicure also priced its public offering of 27,500,000 shares of its...

July 31, 2019

Developments

Orchard Therapeutics gets FDA RMAT designation for Wiskott-Aldrich Syndrome drug

Orchard Therapeutics’ (NASDAQ:ORTX) OTL-103 received FDA regenerative medicine advanced therapy (RMAT) designation for the treatment of Wiskott-Aldrich Syndrome (WAS). WAS is an inherited immune disorder where...

July 31, 2019

Developments

Therapix’s CannAmide approved by Health Canada

Therapix Biosciences (NASDAQ:TRPX) reported that Health Canada issued a product license for CannAmide as an anti-inflammatory, and for relief of chronic pain. CannAmide is an immediate release formulation of the...

July 31, 2019

Developments

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

BELLUS Health (TSX:BLU) enrolled the first patient in its Phase 2 study of BLU-5937 for the treatment of chronic cough. The study, called RELIEF, will assess the efficacy, safety, and tolerability of BLU-5937 at four...

July 31, 2019

Developments

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported that the FDA cleared its IND for a Phase 2 trial of ELX-02 in patients with cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF...

July 31, 2019

Developments

Translate Bio reports interim Phase 1/2 cystic fibrosis trial data

Translate Bio (NASDAQ:TBIO) reported interim results from its Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis (CF). MRT5005 is inhaled to deliver the gene that encodes functional CF transmembrane...

July 31, 2019

HCW starts MediWound at buy; PT $5.50

Piper cuts Intersect ENT to neutral; PT to $17 from $30

AGP cuts T2 Biosystems to neutral; PT 40 cents

AC Immune initiates Phase 1b/2a trial of Alzheimer’s disease vaccine

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

BTIG cuts Conformis to neutral

Exicure to uplist to NASDAQ; prices $55-million public offering

Orchard Therapeutics gets FDA RMAT designation for Wiskott-Aldrich Syndrome drug

Therapix’s CannAmide approved by Health Canada

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Translate Bio reports interim Phase 1/2 cystic fibrosis trial data

General

More